Ironwood Taps Tammi Gaskins as New CEO
IRWD has more than doubled off its 52-week low of $1.43.
Summary
Ironwood Pharmaceuticals named Tammi Gaskins chief executive officer, effective Jan 1, 2027, a leadership change at a company that just returned to profitability. Gaskins will receive a $775,000 base salary, 75% bonus target, and about $4 million in RSU and PSU grants, while McCourt gets $10,000 monthly consulting fee. The appointment lands after a strong Q2 in which Ironwood raised full-year 2026 guidance on 14% LINZESS sales growth to $282 million, repaid $200 million in convertible debt, and posted $51.3 million in quarterly net income. A new CEO inherits that momentum but also sets the strategic direction for the LINZESS franchise and the pipeline. The market will want to know whether Gaskins keeps the current guidance and capital-return posture or resets priorities; no details on her background were provided in the headline.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Gaskins will receive a $775,000 base salary, 75% bonus target, and about $4 million in RSU and PSU grants; McCourt gets $10,000 monthly consulting fee.
At the time of this announcement, IRWD was trading at $3.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $623M. The 52-week trading range was $1.43 to $5.78. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.